Kenney Stephanie 4

4 · Atrium Therapeutics, Inc. · Filed Apr 22, 2026

AI-generated summary of this filing

Updated Apr 22, 2026

Atrium Therapeutics (RNA) Stephanie Kenney Receives RSU & Option Awards

What Happened

Stephanie Kenney, Chief Corporate Affairs Officer of Atrium Therapeutics (RNA), received equity awards reported on Form 4 dated 2026-04-22 for transactions dated 2026-04-20. The filing shows (1) 30,000 restricted stock units (RSUs) granted at $0.00 and (2) a 60,000-share derivative award (option-like grant) granted at $0.00. These were awards (not open-market purchases or sales) and carry no cash purchase price at grant.

Key Details

Transaction date: 2026-04-20; Form 4 filed: 2026-04-22 (timely, two days after the transaction).
Grants: 30,000 RSUs (F1) and 60,000 derivative shares/option-type award (F2); reported price $0.00.
Shares owned after transaction: not specified in the supplied summary of the filing.
Vesting (from filing footnotes):
- F1 (RSUs): 25% vests March 20, 2027, then the remaining RSUs vest in three substantially equal yearly installments thereafter, subject to continuous service.
- F2 (derivative/option): 25% of the underlying shares vest March 20, 2027, then the remainder vests in 36 substantially equal monthly installments thereafter, subject to continuous service.
Filing contains no indication of a 10b5-1 plan, cashless exercise, sale, gift, or tax-withholding disposition in the provided summary.

Context

These are standard time‑based compensation awards to an executive — RSUs convert to shares upon vesting; the derivative award appears to be an option-like grant that vests over time. Because no shares were sold or bought on the open market, this filing documents compensation rather than a market trade and does not by itself indicate an immediate bullish or bearish signal.

Form 4

Period: 2026-04-20

See Remarks

Transactions

Award
Common Stock
[F1]
2026-04-20+30,000→ 35,460 total
Award
Stock Option (Right to Buy)
[F2]
2026-04-20+60,000→ 60,000 total
Exercise: $14.30Exp: 2036-04-20→ Common Stock (60,000 underlying)

Footnotes (2)

[F1]Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
[F2]Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Signature

/s/ Brendan Winslow, Attorney-in-Fact|2026-04-22

1 file